Partnering with Gilead Sciences and the Philippines government to deliver Hepatitis B (HBV) services for rural populations
In this case study, we share how we partnered with Gilead Sciences and the Philippines Department of Health to deliver a comprehensive hepatitis B (HBV) solution for rural populations in the Philippines.
- Challenge
- Approach
- Impact
Hepatitis B (HBV) is a viral infection that attacks the liver and can cause both acute and chronic disease. The World Health Organization (WHO) estimates that in 2015: 257 million persons, or 3.5% of the general population, were living with chronic HBV
HBV represents a major health burden for the Philippines, which has among the highest prevalence in the world. It’s estimated that 1 in 10 Filipinos are living with HBV. Unfortunately, only a small percentage of people are diagnosed due to access to education and screening. Even less have access to medicines for HBV and the life-saving treatments needed.
New public-private partnerships are needed to overcome these access challenges and tackle the HBV through stronger primary healthcare systems and services.
English (UK) 
Bahasa Indonesia